Compare Adaptive Biotechnologies Corp (ADPT) vs Fastly Inc (FSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Fastly Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Fastly Inc trades at $19.09 (market cap $2.91B). The key difference: Adaptive Biotechnologies Corp and Fastly Inc are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Fastly Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | FSLY | |
|---|---|---|
Market Cap | $3.33B | $2.91B |
Sector | Health | Technology |
52-Week High | $22.37 | $33.50 |
52-Week Low | $10.24 | $6.36 |
Enterprise Value | $3.19B | $2.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Fastly (FSLY) trades at $18.59, up 2.54% with a bullish technical signal and positive earnings momentum, having beaten EPS estimates for three consecutive quarters. The company shows improving revenue growth (20% YoY in Q1 2026) and margin expansion, though it remains unprofitable with a -15.79% net income margin. Recent positive developments include Gartner recognition and strategic AI partnerships, while analyst consensus leans neutral with a $25.80 price target representing 39% upside potential.
Fastly presents a growth opportunity in edge cloud infrastructure with strong AI-driven demand, but carries execution risks amid ongoing losses. The stock's valuation at 4.18x sales appears reasonable for a 20% grower, though competitive pressures and high infrastructure spending require careful monitoring. Current technical strength near key support at $18 suggests near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
